Newsroom | 4948 results

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (the “Company”), a world leader in blood glucose monitoring, today announced its successful emergence from its Chapter 11 financial restructuring process following approval of its Plan of Reorganization on October 27, 2025. Through this process, the Company eliminated more than 75% of its debt, providing the financial flexibility needed to continue its leadership in the glucose management industry. In connection with emergence, LifeScan is now owned by a...

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland...

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced a strategic partnership with CLEAR, the secure identity company, to integrate trusted identity verification into its digital health platform. As a CMS Health Tech Ecosystem early adopter, focused on diabetes and obesity patient facing apps, Welldoc is deepening its commitment to CMS’s nationwide initiative through a new partnership with CLEAR. With a shared mission to make health t...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based Cellgorithm™ technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today. In traditional cell differentiation, scientists expose stem cells to a serie...

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world’s #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliv...

MINNEAPOLIS--(BUSINESS WIRE)--Dietitian Live, a pioneering healthcare start-up that merges medical nutrition therapy with subconscious rewiring to reverse chronic disease, today announced a healthcare breakthrough showing that the human brain is the primary driver of healing in chronic metabolic disease. Through its patent-pending Quantum Mind Architecture™ program, the company has demonstrated that when subconscious beliefs are rewired from fear to love, the body’s biology naturally realigns w...

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026. Guided directly by H...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option and a more seamless automated experie...

SAN FRANCISCO--(BUSINESS WIRE)--Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) eine positive Stellungnahme zu BYOOVIZ® Fertigspritzen (PFS) abgegeben hat, einem Biosimilar, das sich auf Lucentis1 (Ranibizumab) bezieht. BYOOVIZ wurde erstmals im August 2021 von der Europäischen Kommission (EK) als Einwegampulle zur intravitrealen Anwendung (0,5 mg/0,05 ml) für die Behandlung der neovaskulären (feuchten) alt...